A time-series analysis on the impact of the antiretroviral treatment program on the burden of hospitalization for culture-confirmed Mycobacterium tuberculosis in Sowetan children by Dangor, Ziyaad
i 
 
                                                                                               
 
A TIME-SERIES ANALYSIS ON THE IMPACT OF THE ANTIRETROVIRAL 
TREATMENT PROGRAM ON THE BURDEN OF HOSPITALIZATION FOR 
CULTURE-CONFIRMED MYCOBACTERIUM TUBERCULOSIS IN SOWETAN 
CHILDREN  
 
 
 
 
 
Ziyaad Dangor 
9901107f 
 
 
 
 
 
 
 
A research report submitted to the Faculty of Health Sciences, University of 
the Witwatersrand, in partial fulfillment for the degree Masters of Medicine in 
Paediatrics (MMed) 
 
Johannesburg 2012 
 
ii 
 
DECLARATION 
 
I, Ziyaad Dangor declare that this research report is my own work. It is being 
submitted for the degree of Masters of Medicine in Paediatrics in the 
University of the Witwatersrand, Johannesburg. It has not been submitted 
before for any degree or examination at this or any other University. 
 
 
………………………… 
 
The ……..day of …………………….,2011 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iii 
 
DEDICATION 
 
I dedicate this work to my dear father, Yusuf Dangor, who has nurtured me 
through this academic endeavor.  I thank him for his encouragement and 
continuous support. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iv 
 
ABSTRACT 
 
Introduction 
 Highly active antiretroviral treatment (HAART) programs in heavily HIV-TB 
burdened countries may reduce the risk of TB in children directly by improving the 
immune system of HIV-infected children; and indirectly by reducing the force of 
transmission from the adult population. The incidence of childhood TB is a sentinel 
measure of the control of infectious adult TB cases in the community. 
 
Objective 
We evaluated the impact that scaling-up of the HAART program in Soweto had on 
the incidence of hospitalization for culture-confirmed TB in children.  
 
Methods  
The study was undertaken in Soweto, where the prevalence of HIV was 4-5% in 
children between 2005 and 2009. The estimated HAART coverage increased from 
43% in 2005 to 84% by 2009 in children with HIV/AIDS. Hospitalized cases of 
culture-confirmed TB in children 3 months to 14 years of age were identified 
through laboratory and clinical electronic databases.  
 
Results 
Overall, the incidence (per 100 000) of hospitalization for culture-confirmed TB 
declined by 58% (95%CI 49.3-65.2) from 2005 (71.4) compared to 2008-9 (30.0); 
p<0.0001. This included a 67% (95%CI 58.5-74.8) reduction in incidence among 
HIV-infected children from 2005 (1 601) compared to 2008-9 (517; p<0.0001). 
v 
 
 In addition, a 33% reduction was observed in HIV-uninfected children (incidence 
19.3 vs 12.9; p=0.016). Fifty-six percent of TB episodes, across all study periods, 
occurred in HIV-infected children who were mainly (76%) severely 
immunocompromised.  
 
Conclusions 
Up-scaling of the HAART program in South Africa has been associated with 
decline in the incidence of culture-confirmed TB, more so in HIV-infected than  
HIV-uninfected children. Severely immunocompromised HIV-infected children, 
however, need to be identified and targeted with HAART and other strategies to 
further reduce the burden of TB in this group.  
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1.0  INTRODUCTION 
 
1.1  Background 
 
South Africa has one of the highest tuberculosis (TB) and human immunodeficiency 
virus (HIV) co-infection burdens in Africa, including in children (1-5). HIV increases 
the risk of progression of Mycobacterium tuberculosis (MTB) infection to disease as 
well as reactivation of latent TB (6). TB impacts negatively on HIV infection by 
accelerating HIV-viral replication and lowering CD4+ T-lymphocyte counts (6-8).  
 
The diagnosis of TB remains challenging in children. Culture of MTB from patient 
samples, whilst the most definitive measure of confirmation of TB in children (9), has 
poor sensitivity (10-30%) for diagnosing TB in children (10,11). Consequently, 
diagnosing childhood TB is mainly based upon non-specific clinical criteria and often 
the use of un-validated algorithms (12).  This is further confounded in HIV-infected 
children, particularly if not receiving highly active antiretroviral treatment (HAART), 
because of the overlap of symptoms and radiological features of TB which are also 
attributable to HIV/AIDS or other non-TB opportunistic infections (13, 14). 
 
In 2004 the South African government initiated a national roll-out of HAART 
management for HIV-infected individuals. Certain clinical and immunological criteria 
needed to be present before instituting treatment. In Gauteng, the overall estimated 
coverage with HAART in HIV-infected children requiring treatment increased from 
21.5% in 2004 to 83.4% in 2009 (15).  
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1.2  Literature review 
HAART has been reported to reduce the incidence of initiation of anti-TB treatment or 
clinical diagnosis of TB in HIV-infected children, compared primarily to historical 
incidence in the same cohort of children whilst not receiving HAART (16-19). These 
studies were all conducted in highly endemic African countries and showed 
reductions of between 50 and 85% in the incidence of TB; however, several 
limitations were present. Unlike adult studies, where the benchmark to diagnosing TB 
is sputum positive culture, the paediatric studies evaluated the impact of HAART 
primarily on cases with a probable or possible diagnosis of TB.  A further limitation 
was that these studies only examined HIV-infected children and are not able to 
deduce whether the changes observed in incidence may have been temporally 
related to other factors related to management of HIV-infected children on HAART. 
The above mentioned studies only focused on children attending HIV clinics and not 
those admitted to hospital with TB which is the primary focus of this study. 
 
Likewise, a similar effect was observed in the adult studies which demonstrated the 
reduction in the incidence of TB in patients on HAART as compared to those not on 
treatment (20-25). Two of these studies looked primarily at the changes in the 
incidence of TB over time, prior to the implementation of HAART as compared to 
when HAART became more available in that setting (20,21). In the study conducted 
by Middelkoop et al. in Cape Town, published in 2011, the case notification rates of 
TB in the adult population increased between 1997 and 2004 by an average of 187 
cases per 100 000/year and peaked at the beginning of 2005. Subsequently the case 
notification rates of TB declined between 2005 and 2008 by 202 cases per 100 
000/year as HAART became more available. The second study conducted by    
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Tseng et al. in Taiwan published in 2009 noted the increasing incidence of TB prior to 
the availability of HAART which was in 1997. The incidence of TB/HIV co-infection 
rose from 1.9% to 3.8% between 1993 and 1998 and decreased from 3.83% to 
0.94% between 1998 and 2006. 
   
The aim of this study was to demonstrate the impact that scaling-up of the HAART 
program in South Africa has had on the incidence of hospitalization for culture-
confirmed TB in children.   
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1.3  Hypothesis and Objectives 
 
Null hypothesis 
 
Increased access to HAART has not reduced the incidence of culture-confirmed 
tuberculosis in a setting with a high prevalence of paediatric HIV infection and high 
incidence of childhood TB.  
 
Primary objective:  
To determine the impact of up-scaling of the antiretroviral treatment program on the 
incidence of culture-confirmed tuberculosis in HIV-infected and HIV-uninfected 
children  
 
Secondary objectives:  
 To determine the in-hospital outcome of children with culture-confirmed TB.   
   To determine the impact of the antiretroviral treatment program on the overall 
burden of tuberculosis (possible, probable and confirmed) in children.   
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2.0  STUDY DESIGN & METHODS 
 
2.1  Study Population 
A retrospective, time-series analysis comparing hospitalization incidence of culture-
confirmed and all-categories of TB in children across the early (2005), intermediate 
(2006, 2007) and established (2008, 2009) HAART eras was undertaken at Chris 
Hani Baragwanath Hospital(CHBH). This hospital serves approximately 1.12 million 
mainly black urban South Africans, including 120 000 children under five years of age 
(15). An estimated 90% of individuals in Soweto requiring hospitalization are admitted 
to CHBH, as less than 10% have medical insurance and CHBH is the only public-
hospital in the study setting. All public-based health care, including access to HAART 
and hospitalization, is provided for free by the state to children.  
 
HIV prevalence and management in study population 
The prevalence of HIV in Gauteng was estimated as being 4-5% in children and 
18%-19% in adults between 2005 and 2009 (15). In the early HAART era it is 
estimated that 42.6% of children eligible for HAART were on treatment as compared 
to the intermediate and established eras where 63.6% and 80.5% respectively were 
on HAART in this province (15). During the study period, the criteria for initiating 
patients on HAART included more than two hospital admissions per year or 
hospitalization for more than four weeks with an HIV related illness; World Health 
Organization (WHO) stage III/IV disease; CD4+ percentage of <20% in children 
under 18 months of age or <15% if over 18 months of age. First line HAART included 
stavudine, lamivudine and lopinavir-ritonavir in children under 3 years of age and less 
than 10 kilograms in weight ; for those over 3 years of age stavudine, lamivudine and 
efavirenz was the recommended first line regimen (26). 
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The prevention of mother to child transmission program (PMTCT) started in South 
Africa in 2001 as a pilot program in a few selected areas. This initial program which 
included single doses of nevirapine to the mother during labour and to the newborn 
following delivery was subsequently rolled out nationally from 2004 onward.  In April 
2008 the PMTCT program was further modified. This included that mothers with 
CD4+ counts <350 were eligible for being initiated on HAART, whilst those with 
CD4+ >350 were provided with zidovudine (AZT) daily during the pregnancy. In 
addition, single dose nevirapine was provided to the mother during labour as well as 
to the newborn at birth. Furthermore, the newborn was provided with twice daily 
zidovudine for 7 to 28 days post-partum, stratified upon whether the mother received 
more than 4 weeks of AZT or HAART treatment during her pregnancy (27). 
 
HIV diagnosis, as standard-of care in children was based on enzyme-linked 
immunosorbent assay (ELISA) test in children older than 18 months of age and HIV-1 
polymerase chain reaction (PCR) reactivity test in children under 18 months of age. 
As there is a high prevalence of HIV in this community, hospital staff routinely council 
parents on HIV testing and request to have their children tested. The majority of 
known HIV-infected children during the course of this analysis would have received 
care at one of two paediatric HIV clinics based at CHBH. Criteria for admission to the 
hospital and investigation for TB of HIV-infected and uninfected children was at the 
discretion of attending physicians in the hospital admission ward.  
 
TB Diagnosis in study population 
The standard of care for diagnosing TB in children hospitalized included having a low 
threshold of performing 2-3 gastric washings or induced-sputum sample collection for 
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MTB culture in children admitted with pneumonia and those with clinical signs and 
symptoms of TB. Other specimens submitted for TB culture when indicated may 
include fine needle aspiration of lymph nodes, tissue specimens from biopsies of 
organs and cerebrospinal fluid. Childhood TB cases were categorized using the 
modified WHO case definitions into three groups namely confirmed, probable and 
possible TB on pre-defined inclusion criteria (28). (Table 1)  
 
Table 1: Inclusion criteria using World Health Organization (WHO) case 
definitions for all forms of childhood tuberculosis. 
 
Confirmed Probable Possible 
Mycobacterium tuberculosis 
cultured from clinical 
specimens in a patient with 
compatible clinical features of 
active tuberculosis 
Acid alcohol fast bacilli 
visualised in clinical 
specimens, without culture 
confirmation of disease caused 
by Mycobacterium tuberculosis  
                  
All children with a discharge 
diagnosis of TB (not meeting 
criteria for confirmed and 
probable TB), identified 
through an electronic database 
of archived discharge 
summaries and admission 
registries to the paediatric 
wards  
 
 
Children under three months of age were excluded from the study on the 
presumption that they may have acquired TB congenitally (29). Other exclusion 
criteria were if the admission records were not traceable, the TB culture result did not 
correlate with the admission or if the results were positive for the same patient less 
than 6 months apart.  
8 
 
Laboratory methods used by the National Health Laboratory Service (NHLS) for 
culturing MTB from sputum and other body fluid cultures (excluding blood) were 
processed using the N-acetyl-L-cysteine-NaOH method. From 2004 until 2006, these 
samples were incubated in the radiometric BACTEC™ 460 TB system (Becton 
Dickinson, Sparks, Maryland) and from 2006 until 2009 the BACTEC™ MGIT 960™ 
TB System (Mycobacterium Growth Indicator Tube) (Becton Dickinson, Sparks, 
Maryland) was used.  Blood for MTB culture was inoculated at the bedside into 
BACTEC™ MycoF/Lytic medium bottles and incubated in the laboratory in the 
BACTEC™ 9240 blood culture system (Becton Dickinson, Sparks, Maryland). Direct 
microscopy of non blood specimens was performed with auramine fluorochrome stain 
with grading according to the WHO/IUATLD system.  
 
2.2  Study Method 
Microbiological records in an electronic database were obtained from the NHLS, 
Department of Microbiology. All children under 15 years of age with MTB culture or 
auramine-smear positive on microscopy were identified. The results were cross 
referenced with the electronic database of archived discharge summaries and 
admission registries to the paediatric wards at CHBH occurring from 1st January 
2005 until 31st December 2009. These results will be time framed into the early 
(2005), intermediate (2006,2007) and established (2008,2009) HAART eras.    
(Figure 1) 
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Figure 1: Schematic representation of study methods used to collect data in 
children with Culture-confirmed TB 
 
 
Children with possible TB were identified through the electronic database of archived 
discharge summaries as those with any discharge diagnosis of TB not meeting the 
criteria for confirmed and probable TB. Outcomes of children hospitalized for culture-
confirmed TB were also reviewed from the electronic discharge database. Children 
were also categorized as having pulmonary or extra-pulmonary TB from the available 
electronic databases and laboratory results. Incidence data were stratified by three 
age groups; 3-23 months, 2-4yrs and 5-14yrs of age. Laboratory results and clinical 
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records were analyzed for HIV status and CD4+ lymphocyte counts. CD4+ counts 
within three months prior to or after the admission were included in the analysis. The 
WHO levels of immune suppression based on CD4+ percentage/count categorization 
were used to stage the extent of immunosupresssion (30).   
 
Permission to conduct the study at CHBH was obtained from the Medical Advisory 
Committee at the hospital. Permission was also obtained from the NHLS for access 
to electronic data and laboratory records. Ethics approval was granted by the Human 
Research Ethics Committee (HREC), University of Witwatersrand. 
 
2.3  Statistical Analysis 
Estimated incidences of TB (culture-confirmed, probable, possible and overall) were 
calculated for the three HAART eras stratified by age and HIV status to yield stratum 
specific incidence rates. Incidence risk ratios (IRR) were calculated by comparing 
group specific incidences for the early, intermediate and established eras of HAART. 
 
The numerators for incidence calculation were the number of TB episodes 
hospitalized during each era; and the population denominator was based on mid-year 
population estimates from the Gauteng Department of Health and Social 
development for region D (Soweto) in Johannesburg as per Statistics South Africa 
report (31). HIV prevalence in the study population was estimated from the 
projections of the AIDS and Demographic models developed by the Actuarial Society 
of South Africa (15). (Table 2) 
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Table 2: Population denominators and HIV prevalence by age-group in Soweto, South Africa1 
 
     
Period Year Age 
Total 
population1 HIV prevalence2 
     
     Early HAART 2005 <2yrs 51 350 5.00% 
  
2 - <5yrs 70 212 5.07% 
  
5 - <10yrs 101 746 2.01% 
  
10 - <15yrs 90 561 0.07% 
     Intermediate HAART 2006 <2yrs 53 865 5.00% 
  
2 - <5yrs 73 743 5.08% 
  
5 - <10yrs 106 074 2.47% 
  
10 - <15yrs 92 385 0.13% 
     Intermediate HAART 2007 <2yrs 52 632 5.00% 
  
2 - <5yrs 74 044 5.08% 
  
5 - <10yrs 110 501 2.94% 
  
10 - <15yrs 96 643 0.22% 
     Established HAART 2008 <2yrs 50 930 5.00% 
  
2 - <5yrs 74 383 5.21% 
  
5 - <10yrs 115 451 3.28% 
  
10 - <15yrs 100 757 0.36% 
     Established HAART 2009 <2yrs 48 785 5.00% 
  
2 - <5yrs 74 788 5.42% 
  
5 - <10yrs 120 930 3.50% 
  
10 - <15yrs 104 683 0.54% 
     
     1Population estimates for region D (Soweto) in Johannesburg as per Statistics South Africa (31) 
2HIV prevalence in the study population was estimated from the projections of the AIDS and Demographic models 
developed by the Actuarial Society of South Africa (15) 
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Unadjusted data were quoted in the results. However, to account for those cases with 
an unknown HIV result, we extrapolated our data to include these cases. The 
unknown cases were divided into HIV-infected or HIV-uninfected based on the 
proportional percentage of known results in the two groups. As a further analysis, we 
extrapolated all the unknown results as HIV-uninfected as the clinician was probably 
not suspecting HIV in them and hence these patients were not tested. 
 
χ2 test (or Fisher’s exact test) were used to compare the distribution of categorical 
variables. 95% confidence intervals were reported and p-values<0.05 were 
considered statistically significant. Demographic data and estimates of incidence and 
risk ratio were analyzed using STATA version11.0 and Epi Info 3.5.1 (CDC, Atlanta, 
USA). 
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3.0  RESULTS 
3.1  Culture-confirmed TB 
The number of cases identified with culture-confirmed TB in 2005 was 224, of which 
132(60%) were HIV-infected. In 2007, 163 cases were identified and in 2009 the 
number of cases dropped to 92. Fifty-six percent of TB episodes, across all study 
periods, occurred in HIV-infected children (Table 3). The median age of presentation 
was 1year 8 months across the five years. Although the median age was higher in 
the 2009 year, these values were not statistically significant when comparing them 
using Chi squared trends. The majority of children with culture- confirmed TB were 
underweight for age with a median z-score of -2.81(range-7.96 to 2.34). The case 
fatality rate of children with culture-confirmed TB over the 5 year period was 
2.9(95%CI 1.9-4.3). Of the 24 fatalities, 15(63%) were HIV infected. Four cases had 
extra-pulmonary TB and the median age was 10months (range: 3months to 12 years) 
(Table 4). 
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Table 3: Number of cases hospitalized for TB stratified by HIV status. 
     
             
 
Overall TB Confirmed TB Probable TB Possible TB 
 
TOTAL PTB EPTB TOTAL PTB EPTB TOTAL PTB EPTB TOTAL PTB EPTB 
   
  
  
  
  
  
   2005 866 760 106 224 197 27 63 59 4 579 504 75 
   
  
  
  
  
  
   HIV-infected 543 485 58 132 117 15 37 35 2 374 333 41 
HIV-uninfected 230 185 45 59 48 11 21 19 2 150 118 32 
HIV-unknown 93 90 3 33 32 1 5 5 0 55 53 2 
   
  
  
  
  
  
   2006 711 609 102 226 194 32 45 42 3 440 373 67 
   
  
  
  
  
  
   HIV-infected 421 370 51 119 104 15 22 20 2 280 246 34 
HIV-uninfected 203 165 38 72 61 11 14 13 1 117 91 26 
HIV-unknown 87 74 13 35 29 6 9 9 0 43 36 7 
   
  
  
  
  
  
   2007 607 487 120 163 129 34 12 11 1 432 347 85 
   
  
  
  
  
  
   HIV-infected 360 287 73 94 75 19 7 6 1 259 206 53 
HIV-uninfected 178 141 37 49 37 12 4 4 0 125 100 25 
HIV-unknown 69 59 10 20 157 3 1 1 0 48 41 7 
   
  
  
  
  
  
   2008 616 490 126 115 90 25 12 10 2 489 390 99 
   
  
  
  
  
  
   HIV-infected 350 269 81 60 46 14 5 5 0 285 218 67 
HIV-uninfected 226 185 41 48 37 11 6 4 2 172 144 28 
HIV-unknown 40 36 4 7 7 0 1 1 0 32 28 4 
   
  
  
  
  
  
   2009 581 467 114 92 69 23 22 19 3 467 379 88 
   
  
  
  
  
  
   HIV-infected 324 253 71 53 39 14 8 7 1 263 207 56 
HIV-uninfected 234 193 41 38 29 9 11 9 2 185 155 30 
HIV-unknown 23 21 2 1 1 0 3 3 0 19 17 2 
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Table 4: Demographic data of children hospitalized with culture-confirmed TB 
     
            
  
2005 
 
2006 
 
2007 
 
2008 
 
2009 
 
            Total no. of cases 
 
224 
 
226 
 
163 
 
115 
 
92 
 Age 
           <2yrs 
 
130 58% 130 58% 85 52% 60 52% 35 38% 
2-4yrs 
 
30 13% 41 18% 26 16% 18 16% 19 21% 
5-14yrs 
 
64 29% 55 24% 52 32% 37 32% 38 41% 
mean(years) 
 
3.25 
 
3.08 
 
3.83 
 
3.75 
 
5yr 
 median(years) 
 
1.25 
 
1.25 
 
1.83 
 
1.75 
 
2.75 
 range 
 
3m-13yrs 
 
3m-14.25yrs 
 
3m-14yrs 
 
3m-13.25yrs 
 
3m-13.83yrs 
 
            Gender 
           M 
 
115 51% 125 55% 92 56% 61 53% 55 60% 
F 
 
109 49% 101 45% 71 44% 54 47% 37 40% 
            Weight for Age(<10yrs) 
           Mean Z-scores 
 
-2.702 
 
-2.847 
 
-2.737 
 
-3.048 
 
-2.743 
 Median Z-scores 
 
-2.64 
 
-2.72 
 
-2.65 
 
-3.28 
 
-2.84 
 Range 
 
-7.08 - 2.34 
 
-7.96 - 0.75 
 
-7.01 - 1.84 
 
-7.57 - 1.78 
 
-6.35 - 2.31 
 
            Outcomes 
                    Discharged 
 
157 
 
208 
 
149 
 
105 
 
89 
 unknown 
 
61 
 
13 
 
10 
 
3 
 
1 
    Demised 
 
6 
 
5 
 
4 
 
7 
 
2 
 Case fatality rate 
 
2.7[1.0-5.7] 
 
2.2[0.7-5.1] 
 
2.5[0.7-6.2] 
 
6.1[2.5-12.1] 
 
2.2[0.3-7.6] 
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3.2  Trends in incidence of culture-confirmed TB 
The incidence (per 100 000) of culture-confirmed TB declined by 58% (95%CI 
49.3-65.2) from the early(2005)HAART era (71.4) compared to the 
established(2008-9)HAART era (30.0); p<0.0001. This included a 67% (95%CI 
58.5-74.8) reduction in incidence among HIV-infected children from the 
early(2005)HAART era (1 601) as opposed to the established(2008-9)HAART era 
(517; p<0.0001). In addition, a 33% reduction was observed in HIV-uninfected 
children (incidence 19.3 vs 12.9; p=0.016). The incidence of culture-confirmed TB 
extrapolated to include all the HIV unknown results as HIV-uninfected 
demonstrated a reduction of 53.3% (95%CI 37.8-65.0; p<0.0001) (Table 5).           
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Table 5: Incidence of culture-confirmed TB for the 3 study periods in children 3 months to 14yrs 
  
       
 
Early-HAART Intermediate-HAART Established-HAART IRR² p=³ %reduction4 
 
Incidence of TB¹ Incidence of TB¹ Incidence of TB¹ 
   
 
[95%CI] [95%CI] [95%CI] 
   
 
(N of TB cases) (N of TB cases) (N of TB cases) 
   
       
       Confirmed TB 71.4[62.3-81.4] 59.0[53.2-65.1] 30.0[26.0-34.3] 0.42[0.35-0.51] <0.0001 58.0[49.3-65.2] 
 
(224) (389) (207) 
   
       
       HIV-infected  1601.4[1341.5-1896.2] 1119.2[974.6-1279.0] 517.2[426.4-621.5] 0.32[0.25-0.41] <0.0001 67.7[58.5-74.8] 
 
(132) (213) (113) 
   
       HIV-uninfected 19.3[14.7-24.9] 18.9[15.7-22.6] 12.9[10.3-15.9] 0.67[0.48-0.93] 0.0155 33.4[7.2-52.2] 
 
(59) (121) (86) 
   
       
       HIV-infected EX 
5
 1880.4[1598.2-2197.3] 1303.1[1146.9-1474.5] 540.1[447.2-646.4] 0.29[0.23-0.36] <0.0001 71.3[63.6-77.4] 
 
(155) (248) (118) 
   
       HIV-uninfected EX 
6
 22.6[17.6-28.6] 22.0[18.5-26.0] 13.3[10.7-16.4] 0.59[0.43-0.81] 0.0009 41.1[19.3-57.0] 
 
(69) (141) (89) 
   
       HIV-uninfected EX
7
 30.1[24.3-36.9] 27.5[23.6-31.8] 14.1[11.4-17.2] 0.47[0.35-0.62] <0.0001 53.3[37.8-65.0] 
 
(92) (176) (94) 
   
       
       ¹ number of cases per 100 000 
     ² incidence risk ratios-Established vs Early HAART era 
    ³ χ² test or Fischer test 
     4 %reduction between Early and Established HAART era 
    5 incidence of TB in HIV-infected extrapolated proportionally to include HIV-unknown  
   6 incidence of TB in HIV-uninfected extrapolated proportionally to include HIV-unknown 
   7incidence of TB in HIV-uninfected extrapolated to include all cases with HIV-unknown 
   
18 
 
3.3  Trends in incidence of culture-confirmed TB stratified by age 
Stratified by age, the incidence of culture-confirmed TB in the 3 to 23 month age 
group decreased (62%; 95%CI 51.0-71.1) across the time periods; from 253.2 per 
100 000 in the early era to 95.3 per 100 000 in the established HAART era; 
p<0.0001 (Figure 1). 
 
 
 
 
Figure 2: Incidence of culture-confirmed TB for the 3 study periods stratified by 
age  
 
 
 
 
 
19 
 
The reduction was more evident in the HIV-infected children, 3 to 23 months, 
among whom the incidence decreased from 2803.7 in the early-HAART era to 
782.2 in the established HAART era, 72.1% reduction (95%CI 58.9-81.1); 
p<0.0001. The incidence of culture-confirmed TB in HIV-infected children in the   
2-4year and 5-14 year age groups also indicated a 65.0%(95%CI 29.8-82.6) and 
66.2% (95% CI 50.0-77.2) reduction respectively when comparing the early and 
established HAART eras (Figure 2). 
 
 
 
 
Figure 3: Incidence of culture-confirmed TB in HIV-infected children for 
the 3 study periods stratified by age  
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There was no statistically significant reduction in HIV-uninfected children in the    
2-4 year and 5-14 year age groups but a reduction of 35.9% (95%CI 33.8-57.5; 
p=0.032) was observed in children 3 to 23 months of age (Figure 3). 
 
 
 
 
Figure 4: Incidence of culture-confirmed TB in HIV-uninfected children 
for the 3 study periods stratified by age  
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3.4  Immunological classification for established HIV infection in children 
hospitalized for culture-confirmed TB 
 
More than two thirds of HIV infected children with culture-confirmed TB had a CD4 
count done within three months of being diagnosed TB culture positive. Seventy-
six percent of these cases across all three study periods occurred in HIV-infected 
children who were categorized as severely immunocompromised (Table 6). 
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Table 6: WHO immunological classification for established HIV infection in children hospitalized for culture-confirmed TB 
         
    
Immunological Classification1 
 
   Year TB cases HIV-infected HIV infected with CD4 Not significant
2 Mild3 Advanced4 Severe5 
  
         2005 224 132 91 9 4 7 71 (78%) 
 
         
         2006 226 119 83 8 2 8 65 (78%) 
 
         
         2007 164 94 66 6 3 7 50 (76%) 
 
         
         2008 115 60 46 3 2 5 36 (78%) 
 
         
         2009 92 53 51 5 2 2 42 (82%) 
 
         
                                              Note: WHO immunological classification1 for established HIV infection(CD4% or absolute number per mm3) 
    
Not significant2 Mild3 Advanced4 Severe5 
 
   
                    <11  months >35% 30-35% 25-29% <25% 
 
   
                     12-35 months >30% 25-30% 20-24% <20% 
 
   
                      36-59 months >25% 20-25% 15-19% <15% 
 
   
         >5yrs >500 350-499 200-349 <200/<15% 
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3.5  Trends in incidence of Overall TB 
The incidence of overall TB (culture-confirmed, probable and possible) declined 
from 275.9 per 100 000 in the early HAART era to 173.3 per 100 000 in the 
established HAART era; p<0.0001. Among HIV-infected children, the incidence of 
overall TB declined by 53.2% (95%CI 47.7-58.1)  in the early HAART era (6587.4) 
compared to established HAART era (3084.8) p<0.0001). No significant reduction 
was noted in HIV-uninfected children (Table 7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
24 
 
Table 7: Incidence of overall TB for the 3 study periods in children 3 months to 14yrs 
   
       
 
Early-HAART Intermediate-HAART Established-HAART IRR² p=³ %reduction4 
 
Incidence of TB¹ Incidence of TB¹ Incidence of TB¹ 
   
 
[95%CI] [95%CI] [95%CI] 
   
 
(N of TB cases) (N of TB cases) (N of TB cases) 
   
       
       Overall TB 275.9[257.9-294.9] 199.7[189.1-211.0] 173.3[163.6-183.4] 0.63[0.58-0.69] <0.0001 37.2[31.5-42.4] 
 
(866) (1318) (1197) 
   
       
       HIV-infected  6587.4[6061.3-7144.5] 4103.8[3826.4-4395.4] 3084.8[2859.5-3322.7] 0.47[0.42-0.52] <0.0001 53.2[47.7-58.1] 
 
(543) (781) (674) 
   
       HIV-uninfected 75.3[65.9-85.6] 59.4[53.6-65.7] 68.8[62.6-75.4] 0.91[0.78-1.07] 0.2644 8.6[-7.1-22.0] 
 
(230) (381) (460) 
   
       
       HIV-infected EX 
5
 7376.0[6820.8-7961.5] 4655.6[4360.6-4964.5] 3254.2[3022.8-3498.0] 0.44[0.40-0.49] <0.0001 55.9[51.0-60.3] 
 
(608) (886) (711) 
   
       HIV-uninfected EX 
6
 84.4[74.4-95.4] 67.4[61.2-74.1] 72.7[66.4-79.4] 0.86[0.74-1.00] 0.0513 13.9[-0.1-26.0] 
 
(258) (432) (486) 
   
       
       ¹ number of cases per 100 000 
     ² incidence risk ratios-Established vs Early HAART era 
    ³ χ² test or Fischer test 
     4 %reduction between Early and Established HAART era 
    5 incidence of TB in HIV-infected extrapolated proportionally to include HIV-unknown  
   6 incidence of TB in HIV-uninfected extrapolated proportionally to include HIV-unknown 
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3.6  Trends in incidence of probable TB 
A 75% (95%CI 62.8-83.8) reduction was demonstrated for probable TB between 
the early (20.1 per 100 000) and the established (4.9 per 100 000) HAART era; 
p<0.0001. There was an 86% (95%CI 75.1-93) reduction in incidence among HIV-
infected children from early HAART era  (448.9) compared to the established 
HAART era (59.5); p<0.0001. In addition, a 63% (95%CI 29.9-80.5) reduction was 
observed in HIV-uninfected children (incidence 6.9 vs 2.5; p=0.015) (Table 8). 
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Table 8: Incidence of probable TB for the 3 study periods in children 3 months to 14yrs 
   
       
 
Early-HAART Intermediate-HAART Established-HAART IRR² p=³ %reduction4 
 
Incidence of TB¹ Incidence of TB¹ Incidence of TB¹ 
   
 
[95%CI] [95%CI] [95%CI] 
   
 
(N of TB cases) (N of TB cases) (N of TB cases) 
   
       
       Probable TB 20.1[15.4-25.7] 8.6[6.5-11.2] 4.9[3.4-6.9] 0.25[0.16-0.37] <0.0001 75.5[62.8-83.8] 
 
(63) (57) (34) 
   
       
       HIV-infected  448.9[316.2-618.2] 152.4[102.1-218.8] 59.5[31.7-101.7] 0.13[0.07-0.25] <0.0001 86.7[75.1-93.0] 
 
(37) (29) (13) 
   
       HIV-uninfected 6.9[4.3-10.5] 2.8[1.7-4.4] 2.5[1.5-4.1] 0.37[0.20-0.70] 0.0015 63.0[29.9-80.5] 
 
(21) (18) (17) 
   
       
       HIV-infected EX 
5
 485.3[346.9-660.2] 189.2[132.5-261.8] 64.1[35.0-107.5] 0.13[0.07-24.2] <0.0001 86.8[75.7-92.8] 
 
(40) (36) (14) 
   
       HIV-uninfected EX 
6
 7.5[4.8-15.7] 3.3[2.0-5.0] 3.0[1.8-4.6] 0.40[0.22-0.72] 0.0018 60.3[27.7-78.2] 
 
(23) (21) (20) 
   
       
       ¹ number of cases per 100 000 
     ² incidence risk ratios-Established vs Early HAART era 
    ³ χ² test or Fischer test 
     4 %reduction between Early and Established HAART era 
    5 incidence of TB in HIV-infected extrapolated proportionally to include HIV-unknown  
   6 incidence of TB in HIV-uninfected extrapolated proportionally to include HIV-unknown 
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3.7  Trends in incidence of possible TB 
Possible TB had minimally declined from 579 cases in 2005 to 467 cases in 2009. 
The incidence of possible TB had not significantly changed when comparing the 
2006/7 and 2008/9 periods but did show a decline of 25.0% (95%CI 16.8-32.3) 
when comparing the early (184.5 per 100 000) and established (138.4 per 100 
000) HAART eras; p<0.0001 (Table 9). 
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Table 9: Incidence of possible TB for the 3 study periods in children 3 months to 14yrs 
   
       
 
Early-HAART Intermediate-HAART Established-HAART IRR² p=³ %reduction4 
 
Incidence of TB¹ Incidence of TB¹ Incidence of TB¹ 
   
 
[95%CI] [95%CI] [95%CI] 
   
 
(N of TB cases) (N of TB cases) (N of TB cases) 
   
       
       Possible TB 184.5[169.8-200.1] 132.1[123.5-141.2] 138.4[129.8-147.5] 0.75[0.68-0.83] <0.0001 25.0[16.8-32.3] 
 
(579) (872) (956) 
   
       
       HIV-infected  4537.2[4098.0-5008.9] 2832.2[2601.1-3077.9] 2508.1[2304.8-2724.2] 0.55[0.49-0.63] <0.0001 44.7[37.1-54.4] 
 
(374) (539) (548) 
   
       HIV-uninfected 49.1[41.5-57.6] 37.8[33.2-42.8] 53.4[48.0-59.2] 1.09[0.90-1.32] 0.3883 Nil 
 
(150) (242) (357) 
   
       
       HIV-infected EX 
5
 5010.3[4549.3-5503.5] 3158.0[2914.1-3416.7] 2650.0[2441.1-2871.7] 0.53[0.47-0.60] <0.0001 47.1[40.1-53.2] 
 
(413) (601) (579) 
   
       HIV-uninfected EX 
6
 54.3[46.4-63.2] 42.3[37.4-47.6] 56.4[50.8-62.4] 1.04[0.86-1.25] 0.6907 Nil 
 
(166) (271) (377) 
   
       
       ¹ number of cases per 100 000 
     ² incidence risk ratios-Established vs Early HAART era 
    ³ χ² test or Fischer test 
     4 %reduction between Early and Established HAART era 
    5 incidence of TB in HIV-infected extrapolated proportionally to include HIV-unknown  
   6 incidence of TB in HIV-uninfected extrapolated proportionally to include HIV-unknown 
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4.0  DISCUSSION 
 
The introduction of HAART into the public health program in a South African 
setting with a high co-burden of HIV-TB in children has been temporally 
associated with a drastic decline in hospitalization for culture-confirmed TB among 
both HIV-infected and less so, HIV-uninfected children. In particular, whilst HAART 
treatment of HIV-infected children may have accounted for the reduction in 
emperic initiation of anti-TB or clinical diagnosis of TB in other pediatric studies 
(16-19), the observation of a decline in microbiologic confirmed TB in our study 
provides the most definitive evaluation on the impact of up-scaling of the HAART 
program on childhood TB in a country with a high burden of TB and HIV. In 
addition, the decline of culture-confirmed TB in young HIV-uninfected children 
observed in our study, may be due to reduced pressure of TB transmission within 
the community, possibly resulting from the up-scaling of the HAART program in 
HIV-infected adults in the same community as demonstrated in a study by 
Middelkoop et al.(20) in Cape Town between 2005 and 2008 (TB incidence; 6 513 
to 4 714 per 100 000). 
  
Although HIV-infected children may also have benefited from a reduced load of 
infectious cases of TB because of treatment of HIV-infected adults with HAART, 
the greater magnitude of decline observed in  HIV-infected compared to HIV-
uninfected children indicates the added benefit of adequately treating these 
children with HAART. Nevertheless, despite the decline in incidence of TB in HIV-
infected children, the burden of culture-confirmed TB in our study remained         
40 (95%CI 30.4-53.2) fold greater compared to HIV-uninfected children in 2008-9.    
In comparison, a study conducted in Cape Town  in 2008 by Hesseling et al.(32), 
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demonstrated the incidence of culture-confirmed TB between 2004 and 2006 in 
HIV-infected and uninfected infants as 1 596 per 100 000 and 65.9 per 100 000 
respectively. Her study reported the relative risk of culture-confirmed TB in HIV-
infected as 24.2 (95%CI 17-34) as compared to HIV-uninfected infants. 
 
The magnitude of burden of disease is clearly in children under 2 years of age. 
The most dramatic decline in incidence was evident in this group in both HIV-
infected and HIV-uninfected children. Data available from the PCV study 
conducted by Moore et al.(33) in Soweto between 1998 and 2005 described the 
incidence of culture-confirmed TB as 321.4(95%CI 247.5-410.4) in children under 
2 years of age over that period. The incidence of culture-confirmed TB in HIV-
infected children was reported as 3 183.2 (95%CI 2284.3-4318.4) in children 
under 2 years of age. Similarly, our data in children under 2 years of age 
demonstrated an incidence of culture-confirmed TB as 253.2 (95%CI 211.6-300.5) 
and in HIV-infected of 2 803.7 (95%CI 2200.1-3518.0) per 100 000 in 2005; hence 
we can appreciate the reduction in the incidence of culture-confirmed TB as the 
coverage of HAART increased. 
 
When extrapolating the numbers of unknown HIV results proportionally into both 
HIV-infected or HIV-uninfected groups, we demonstrated a 4% (67 vs 71) greater 
reduction in the incidence of culture-confirmed TB in the HIV-infected group 
comparing the early and established HAART eras (Table 5). This highlights that 
we may have marginally underestimated the effect that HAART has had on the 
incidence of culture-confirmed TB in HIV-infected children. 
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As a further analysis, we extrapolated all the unknown HIV results as HIV-
uninfected based on the likelihood that these children had no clinical evidence of 
HIV and were thus not tested. This indicated a reduction of 53.3% (95%CI 37.8-
65.0) in HIV-uninfected children with culture-confirmed TB when comparing the 
early and established HAART era (Table 5). Thus the unadjusted reduction in the 
HIV-uninfected may have been an underestimate of the true impact of reduced 
transmission of TB in the community. 
 
Furthermore, our data reflects that of the HIV-infected children hospitalized for 
culture-confirmed TB, seventy six percent had severe immunosuppression. This  
compares to a study conducted in Cape Town in 2008 by Hesseling et al.(32) 
which demonstrated a mean CD4+  of 10.7% in HIV-infected children, 
corroborating our findings that much of the residual burden of TB as occurring in 
severely immuncompromised children and highlighting the gaps in the HAART 
program during our study period.  
 
Most paediatric studies demonstrating the decline in the incidence of TB compared 
patients who were not on HAART versus those on HAART. The diagnosis of TB 
was made primarily on clinical diagnosis, rather than microbiologic confirmed 
cases and may have over-estimated the effect of HAART on the burden of TB in 
HIV-infected children (16-19). The only study to have reported an association of 
HAART and reduction in culture-confirmed TB among HIV-infected children was 
by Martinson et al. (16). His study confirmed TB in 23% of the cases but only 
showed a reduction in the incidence of TB in this confirmed group of 3.8/100py to 
2.7/100py as compared to all cases of TB where the incidence was reduced    
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from 21.1/100py to 6.4/100py. On the other hand, a prospective study conducted 
by Frigati et al. (34) from 2003 to 2007 in Cape Town demonstrated that HAART 
reduced TB risk by 0.32 (95% CI 0.07-1.55) in HIV-infected children. However, this 
result was statistically not significant.  
 
Identifying TB bacilli by microscopy is uncommon in children and this is evident by 
the low numbers of cases in our sample population (35). Despite this, we noted a 
significant reduction in the incidence of only smear-positive cases of TB (20.1 to 
4.9 per 100 000; p<0.0001). Clinically diagnosed TB had only declined by 
25%(95%CI 16.8-32.3) over the time period of the study. This highlights the 
difficulties clinicians continue to face when diagnosing TB in children and many a 
time over-diagnosing TB in HIV-infected children. 
 
The number of cases with culture-confirmed extra-pulmonary TB remained fairly 
consistent over the study period. Evidence suggests that extra-pulmonary TB is 
not disproportionately increased in HIV-infected children (32,36). In our study, we 
also noted no significant changes in the cases of extra-pulmonary TB as HAART 
became more accessible. However, it should be noted that our study was not 
powered to make this conclusion. 
 
The first limitation to this study was that we used a cohort of only hospitalized 
patients with TB and thus we may have underestimated the overall burden of TB in 
this population. However, it should be noted that until 2010 most if not all HIV-
infected children in this region were treated at the two HIV in-hospital clinics and 
thus would be admitted for diagnostic work up and treatment.  
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A second limitation is that there may have been changes in clinician behavior in 
terms of referral, admission and investigating children with suspected TB over the 
time period of the study. The DOTS program, its successes and failures has not 
been measured. The health departments’ surveillance and identification of source 
cases may have also had an impact. The absence of information on clinical and 
immune responses to HAART and treatment failures on individual subjects is a 
further limitation.   
 
 A third limitation is that we have not taken into account whether cases received 
primary or secondary prophylaxis for TB. However, in a recent study conducted by 
Madhi et al. in 2011 in South Africa, no benefit of primary isoniazid(INH) 
prophylaxis in children was demonstrated (37).  
 
A fourth limitation was the change over in the laboratory methods used to culture 
TB; from the radiometric BACTEC™ 460 TB system used from 2004 to 2006 to 
the BACTEC™ MGIT 960™ TB System used thereafter. The main reason for this 
change was a move away from radioactive hazard of the radiometric BACTEC™ 
460 system. The BACTEC 460 has been shown to be slightly superior to the MGIT 
in terms of yield as there is less contamination of specimens (38).  
 
Unfortunately, due to the lack of available data on patient outcomes in our 
database, we were only able to classify the patient outcomes as discharged, 
demised or unknown. We did attempt to retrieve more detail on the missing 
outcomes by reviewing the hospital registries and patient files but those later than 
5 years were inaccessible; this explains the high number of unknown outcomes in 
the year 2005. 
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Another limitation to this study was that we used population estimates as our 
denominator for this study region (31). We did not account for any influx of children 
to this region over the study period. However as a separate analysis using the total 
number of patients hospitalized as a denominator (39), similar declines were 
shown. 
 
A further limitation was the coverage of HIV-infected children on HAART which 
was already estimated at 43% in 2005. Ideally we would have liked to analyzed 
data prior to 2005, when the coverage with HAART was lower. Regardless, a 
temporal association between increased coverage of HAART and the incidence of 
culture confirmed TB is apparent.  
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5.0  CONCLUSION 
Up-scaling of the HAART program in South Africa has resulted in a dramatic 
decline in the incidence of culture-confirmed TB in HIV-infected children, as well 
as possibly indirectly in HIV-uninfected children. The greatest impact was 
observed in children under two years and this highlights the need for targeting 
these children with HAART early in the course of their HIV infection. The indirect 
effect in HIV-uninfected children may have been attributable to a decreased level 
of TB transmission in the adult population, however the magnitude of burden of 
disease in the HIV-infected children remained 40 fold greater at the end of our 
study period. Severely immune-compromised HIV-infected children need to be 
targeted with antiretroviral treatment in addition to other strategies to further 
reduce the burden of TB.  
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6.0  RECOMMENDATIONS 
This study provides some long-awaited optimistic news in the battle against HIV 
and TB. Since 2010 the Department of Health has further improved the 
antiretroviral treatment program in South Africa. These included changes to the 
PMTCT program as well as starting all infants on treatment regardless of staging 
of disease. It will be useful to measure the impact this has had in the next 5 years 
as we continue the fight against this dual pandemic. A further useful study will be 
to measure the impact that the introduction of the pneumococcal vaccine has had 
on the burden of TB in this setting (40).  
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